Levemir News and Research

RSS

An Arm and a Leg: Wait, is Insulin cheaper now?

Pharmaceutical companies that manufacture insulin made headlines last year when they voluntarily agreed to provide discount cards that lower the monthly cost of insulin for many people to $35.

28 Feb 2024

KFF Health News' 'What the Health?': The struggle over who gets the last word

The Supreme Court in March will hear oral arguments in two very different cases that boil down to the same question: How much power do "experts" in health and science deserve? At stake is the future accessibility of the abortion pill mifepristone, and the ability of government officials to advise social media companies about misinformation.

1 Feb 2024

How a drug company under pressure for high prices ratchets up political activity

Business looked challenging for Novo Nordisk at the end of 2016. As pressure mounted over the pharma giant's soaring insulin prices, investors drove its stock down by a third on fears that policymakers would take action, limit prices and hurt profits.

30 Apr 2018

T1DM therapeutics market expected to reach $7.1 billion by 2021

Analysis from business intelligence provider GBI Research - Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - states that the global market value for T1DM treatment will rise from $4.2 billion in 2014 to $7.1 billion by 2021, at a robust Compound Annual Growth Rate (CAGR) of 7.9%.

24 Nov 2015

Levemir FlexTouch insulin pen receives approval from Health Canada for treatment of diabetes

Novo Nordisk today announced that Health Canada has approved Levemir® FlexTouch®, a disposable prefilled insulin pen containing Levemir® (insulin detemir). Levemir® FlexTouch® has been designed to improve ease of use for insulin administration and to help decrease barriers to good treatment adherence for Canadians living with type 1 and type 2 diabetes mellitus (diabetes).

19 Oct 2013

Novo Nordisk first quarter net profit increases 23% to DKK 4,073 million

Novo Nordisk has completed a pre-specified meta-analysis based on the Degludec phase 3a trial programme. The meta-analysis confirmed that Degludec is associated with a lower risk of hypoglycaemia compared to insulin glargine, both on the total number of confirmed hypoglycaemic events, and on the number of confirmed nocturnal hypoglycaemic events. Both findings are statistically significant.

From Novo Nordisk 28 Apr 2011

Novo Nordisk announces $73M expansion of Clayton insulin delivery systems manufacturing facility

Novo Nordisk, a global healthcare company and leader in diabetes care, today announced a $73 million expansion of its Clayton, NC manufacturing facility to accommodate increased production capacity for the Company's insulin delivery devices.

5 Oct 2010

SDI Pharmaceutical Company Image 2010 study: Novo Nordisk ranked top among endocrinologists

According to SDI's Pharmaceutical Company Image 2010 study, Novo Nordisk was ranked by endocrinologists as the top company overall. The company was mentioned by 62% of the endocrinologists who participated in the annual study - a substantial increase from last year, when it was mentioned by 52% of participants and ranked second.

7 Jul 2010

Additional benefits of LAIAs over long-acting human insulin not been proven

It has so far not been proven that the long-acting insulin analogues (LAIAs) insulin detemir (trade name: Levemir) and insulin glargine (trade name: Lantus), which are approved for the treatment of type 1 diabetes, offer patients an additional benefit versus long-acting human insulin. This applies to adults as well as to children and adolescents. This is the result of the final report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 19 April 2010.

13 May 2010

Report on the type 2 diabetes drug market in Brazil

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the type 2 diabetes drug market in Brazil will grow from $417 million in 2008 to $834 million in 2013.

3 Dec 2009

Novo Nordisk's Levemir not associated with increase in the incidence of cancer

A meta-analysis of clinical data published today in Diabetologia, the medical journal for the European Association for the Study of Diabetes (EASD), demonstrated that the Novo Nordisk long-acting insulin Levemir® (insulin detemir [rDNA origin] injection) was not associated with any increase in the incidence of cancer when compared to human insulin.

From Novo Nordisk 21 Oct 2009

Decision Resources forecasts biosimilar insulins and insulin analogues to erode $6.1 billion in brand sales

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilar insulins and insulin analogues stand to erode $6.1 billion in brand sales in the U.S. and Europe (France, Germany, Italy, Spain and U.K.) by 2018, saving healthcare systems $3.8 billion in the process.

15 Oct 2009

FDA releases latest listing of consumer health information updates

The U.S. Food and Drug Administration today released its latest listing of consumer health information updates. All articles can be accessed from the agency's Web page for consumers at http://www.fda.gov/ForConsumers/default.htm.

14 Sep 2009

Saskatchewan government makes insulin detemir more accessible to residents

The Canadian Diabetes Association applauds the Government of Saskatchewan for increasing access to insulin detemir for residents of Saskatchewan living with diabetes. Insulin detemir, also known as Levemir, has been added to the Saskatchewan Drug Formulary, under Exception Drug Status (EDS) effective July 1, 2009. As well, the updated formulary now includes NovoRapid-NOO, Apidra-AVT and Humalog-LIL within its Revised Exception Drug Status Criteria.

20 Aug 2009

Possible link between insulin glargine and cancer prompts urgent call for more research

The European Association for the Study of Diabetes (EASD) has made an urgent call for more research into a possible link between use of insulin glargine (an insulin analogue) and increased risk of cancer, following evidence from studies in Germany, Sweden and Scotland. However, until this further research becomes available, these experts are stressing that patients with diabetes taking Lantus should continue to do so, although some might wish to consider alternative types of insulin. The studies are reported in Diabetologia (the journal of EASD), edited by Professor Edwin Gale of the University of Bristol.

28 Jun 2009

FDA issues health advisory on Levemir insulin

The U.S. Food and Drug Administration has learned that some stolen vials of the long-acting insulin Levemir made by Novo Nordisk Inc. have reappeared and are being sold in the U.S. market.

13 Jun 2009

Standard long-acting insulin as good as newer medications

An older type of long-acting insulin is as effective in treating type 2 diabetes as newer and more expensive kinds, according to the results of a recent systematic review.

19 Apr 2007